npj Vaccines (Feb 2022)

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

  • Michael Karbiener,
  • Maria R. Farcet,
  • Andreas Zollner,
  • Taisei Masuda,
  • Mitsuhiro Mori,
  • Alexander R. Moschen,
  • Thomas R. Kreil

DOI
https://doi.org/10.1038/s41541-022-00455-3
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 3

Abstract

Read online

Abstract SARS-CoV-2 neutralizing antibodies have been suggested to reflect the efficacy of COVID-19 vaccines. This study reports the direct comparison of the SARS-CoV-2 neutralizing antibody response elicited by a protein- (NVX-CoV2373), an mRNA- (Comirnaty), and a vector-based (Vaxzevria) COVID-19 vaccine, calibrated against the WHO international SARS-CoV-2 antibody standard, and further supports the use of neutralizing antibody levels as a correlate of protection.